Posts Tagged 'Januvia'

Merck recalling heart medication

Pharmaceutical giant Merck is withdrawing its heart drug Tredaptive from the market in 40 countries after a study showed that it didn’t work, and caused more serious side effects than placebos.

A report on NPR says the drug was meant to prevent heart disease and stroke by promoting good cholesterol. It combines the vitamin niacin and laropiprant, a chemical that reduces the unpleasant skin flushing caused by high doses of niacin.

Other Merck medications have generated concerns recently. Januvia, the company’s treatment ...

continue reading...

FDA advisers recommend approval of diabetes medication

A panel of advisers to the U.S. Food and Drug Administration voted 10-5 that Johnson & Johnson’s diabetes drug should be approved, although they also voted 8-7 that it also raises concerns about heart risks.

According to Bloomberg, the once-a-day pill that the company has proposed calling Invokana is part of a group of medications known as SGLT2 inhibitors, which are intended to minimize side effects such as low blood sugar and weight gain compared to current diabetes drugs.

Johnson & Johnson ...

continue reading...

Diabetes drug works in late-stage trials

Pharmaceutical companies Eli Lilly and Co and Boehringer Ingelheim announced that their type 2 diabetes treatment, empagliflozin, has been shown to work in four late-stage trials.

According to a Reuters report, the companies expect to file for regulatory review of the drug in the United States, Europe and Japan in 2013, and will present detailed data from the trials.

Diabetes treatment is a potentially lucrative market, especially in light of recent health concerns ...

continue reading...

Diabetes drug creates risk for kidney problems

A report in Health Magazine says the type 2 diabetes drug Byetta could put patients at risk for kidney problems, including kidney failure.

According to the report, Byetta is a relatively new drug that’s proven popular because it can promote weight loss and it’s easier to inject than insulin.

But within two years of its approval in 2005, it was linked to a higher risk of acute pancreatitis, which is a potentially life-threatening inflammation of the pancreas that can lead to pancreatic ...

continue reading...

FDA Claims Manufacturer Withheld Info

According to U.S. Food and Drug Administration documents, the manufacturer of diabetes drug Byetta tried to conceal from federal regulators a study that linked the drug to potential heart problems.

In large part because of Amylin Pharmaceuticals’ deceitfulness, The Street reports, the FDA rejected another diabetes drug the company submitted for approval. And Amylin Pharmaceuticals subsequently misled investors about the reason for that rejection.

According to The Street, Amylin has been selling Byetta since 2005.

The drug has since generated some safety concerns. ...

continue reading...

Diabetes drug looks good in study

The blog FiercePharma reports that the diabetes drug Victoza has performed well in a clinical study – performing better than competitors Januvia and Byetta in keeping patients’ blood sugar below a target of 7 percent.

Novo Nordisk, Victoza’s manufacturer, is working to secure more of an edge in what the blog entry describes as “the fast-growing diabetes market.” But it will likely face challenges in the form of a marketing blitz from ...

continue reading...
Page 11 of 13 «...910111213